• Droia Ventures portfolio company Alesta Therapeutics agreed to be acquired by BioMarin for USD 275 million upfront.
• Deal includes up to USD 215 million in development and regulatory milestones; BioMarin plans to fund the transaction with cash.
• Acquisition adds ALE1, an oral small-molecule in Phase 1/2a for hypophosphatasia, to BioMarin’s clinical-stage pipeline.
• Alesta will spin out non-ALE1 assets before closing; Alesta employees will transfer to the spinout, not BioMarin.
• BioMarin expects a modestly dilutive impact on 2026 results, excluding the upfront payment; closing is expected this quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Droia Ventures published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.